Globe Roche Logo

Working hand in hand to provide innovative diagnostic solutions to those who need it most

More than 35 million people are currently living with HIV

Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organizations have joined together with an ambitious goal: ending the HIV/AIDS pandemic.

As the leading provider of HIV viral load testing, Roche created the Global Access Program to contribute to the UNAIDS 90-90-90 goal, expanding access to quality, sustainable diagnostic testing for countries hardest hit by HIV.

"We applaud all the global partners who came together to ensure that over 31 million people living with HIV/AIDS in low- and middle-income countries will be able to access viral load testing at this reduced price."  –  President Bill Clinton, Chairman of the Clinton Health Access Initiative

"We welcome this significant price breakthrough–the urgent call of people living with HIV is being answered. Now, with viral load testing, we can help ensure HIV treatment improves quality of life."  –  Michel Sidibé, UNAIDS Executive Director

Visit Booth 320 at AIDS 2018

The fight against HIV and AIDS continues

Join us at the International AIDS Conference in Amsterdam from July 23-27 to learn more about Roche’s commitment to providing life-saving diagnostics in the fight against HIV and AIDS.

The theme of AIDS 2018 is “Breaking Barriers, Building Bridges”. This aims to promote human rights-based and evidence-informed HIV responses with a focus on vulnerable communities where the epidemic is growing; such as Eastern Europe and Central Asia and the North-African/Middle Eastern regions.

Roche’s ground-breaking Global Access Program was initiated after the 20th International AIDS conference in July 2014 when Roche partnered with national governments, local healthcare facilities, communities and international agencies.

To discover more about our diagnostics solutions and the Global Access Program, see us at booth 320.

Learn more

cobas® Plasma Separation Card

Redefine the reach of reliaple testing. The cobas® Plasma Separation Card makes reliable, quantitative HIV testing more accessible to those in the remote areas.


Your resource for diagnostics that make a difference

The Global Access Program underscores Roche’s ongoing commitment to providing life-saving diagnostics in the fight against HIV and AIDS. Download our Resource Kit and join Roche in ensuring equal access around the globe.

Share our story

HIV at a glance

Get a visual overview of the HIV landscape, before and after the start of global awareness initiatives.

See infographic

90-90-90 lays the groundwork for achieving global HIV viral suppression

By 2020...

diagnosed ...of people living with HIV know their HIV status
on treatment ...of people who know their status receive treatment
virally suppressed ...of people on HIV treatment have a suppressed viral load

90-90-90 aims to increase HIV viral suppression to 73% worldwide by 2020 1-3

*Adults and children estimated to be living with HIV in 2014 and 2020, assuming infection rates remain the same.

Targeting 90-90-90 with optimized diagnostic testing

The Global Access Program contributes to the goals of 90-90-90 by providing diagnostic products for early infant diagnosis and viral load testing.

Early Infant Diagnosis

Early diagnosis in infants and young children is a major challenge—antibody tests are ineffective due to maternal antibodies remaining in the child. The Roche HIV Qualitative assay provides reliable, accurate information on whether or not an infant is infected.

Dry Blood Spot
The use of dried blood spots is an increasingly sustainable solution which allows for PCR testing. Collecting small blood on a specially designed collection card facilitates easy sample transportation and storage, and is ideal for resource-limited areas.

Increase in antiretroviral therapy for children less than 15 years old
From 566,000 in 2011 to 630,000 in 2012 in low- and middle-income countries4

Increase in percentage of pregnant women receiving antiretroviral medication for an HIV infection
From 49% in 2009 to 65% in 20124

Decline in mother-to-child transmission rates
26% in 2009 down to 17% in 20124

Child HIV infections prevented with effective antiretroviral regimens & PMTCT programs
800,000 between 2005 and 20124 PMTCT=Prevent Mother to Child Transmission

Learn more about the critical importance of early infant diagnosis

Download Brochure

Viral Load Testing

Roche is a global market leader in HIV viral load testing, a method for determining the amount of HIV circulating in a body. Testing for viral load can confirm if patients are responding to medication, or if second-line therapies should be considered.


Register here to receive regular updates about the Global Access Program

*Mandatory fields


  1. UNAIDS Core Epidemiology Slides, July 2015. Accessed June 13, 2016.
  2. UNAIDS Report on the global AIDS epidemic. 2010. Accessed June 13, 2016.
  3. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. 2014. Accessed June 13, 2016.
  4. Pavia AT. Primary care of infants and children with HIV. Accessed June 13, 2016.
  5. UNAIDS 2013 | AIDS by the numbers. Accessed June 13, 2016.